Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

BACKGROUND: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. METHODS: We conducted an Asian multinational phase II study for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Kurokawa, Yukinori, Yang, Han-Kwang, Cho, Haruhiko, Ryu, Min-Hee, Masuzawa, Toru, Park, Sook Ryun, Matsumoto, Sohei, Lee, Hyuk-Joon, Honda, Hiroshi, Kwon, Oh Kyoung, Ishikawa, Takashi, Lee, Kyung Hee, Nabeshima, Kazuhito, Kong, Seong-Ho, Shimokawa, Toshio, Yook, Jeong-Hwan, Doki, Yuichiro, Im, Seock-Ah, Hirota, Seiichi, Hahn, Seokyung, Nishida, Toshirou, Kang, Yoon-Koo
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2017
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520207/
https://ncbi.nlm.nih.gov/pubmed/28535156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados